-
公开(公告)号：US20210340254A1
公开(公告)日：2021-11-04
申请号：US17376314
申请日：2021-07-15
Applicant: INNATE PHARMA
Inventor： LAURENT GAUTHIER , NICOLAS SCHNEIDER
Abstract: The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.
-
公开(公告)号：US20190276536A1
公开(公告)日：2019-09-12
申请号：US16398472
申请日：2019-04-30
Applicant: INNATE PHARMA
Inventor： LAURENT GAUTHIER , NICOLAS SCHNEIDER
Abstract: The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.
-
公开(公告)号：US20170158763A1
公开(公告)日：2017-06-08
申请号：US15125216
申请日：2015-03-12
Applicant: INNATE PHARMA
Inventor： LAURENT GAUTHIER , NICOLAS SCHNEIDER
IPC: C07K16/28
CPC classification number: C07K16/2803 , A61K9/0019 , A61K39/39591 , A61K47/02 , A61K47/12 , A61K47/26 , A61K2039/505 , C07K16/3061 , C07K2317/24 , C07K2317/52 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/732 , C07K2317/76 , C07K2317/94
Abstract: The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.
-
-
Search Results
3
records
(took 0.01 seconds)
